Screener
Sarepta Therapeutics, Inc. SRPT Business Segments — Impairment Of Strategic Investments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept srpt:ImpairmentOfStrategicInvestments.
The source filing: Sarepta Therapeutics, Inc.’s 10-K, filed March 2, 2026.
- Filed
- Mar 2, 2026, 7:02 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-084144
| Line item | For the Year Ended December 31, 2025 | For the Year Ended December 31, 2024 | For the Year Ended December 31, 2023 |
|---|---|---|---|
| Depreciation and amortization expense | 44,521 | 37,724 | 44,397 |
| Stock-based compensation expense | 123,396 | 184,300 | 182,514 |
| Gain from sale of Priority Review Voucher | — | — | (102,000) |
| Impairment of strategic investments | — | — | 30,321 |
| Segment net (loss) income | $(713,410) | $235,239 | $(535,977) |
| Reconciliation of profit or loss | |||
| Adjustments and reconciling items | — | — | — |
| Consolidated net (loss) income | $(713,410) | $235,239 | $(535,977) |
Item 16. Form 10-K Summary.
FAQ
- What is Sarepta Therapeutics, Inc.'s business segments — impairment of strategic investments?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — impairment of strategic investments of $0 in Q4 2025.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — impairment of strategic investments?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — impairment of strategic investments has grown at a -100.0% compound annual growth rate (CAGR), from $2.58M to $0.
- What does business segments — impairment of strategic investments mean?
- This metric quantifies the write-down in the carrying value of strategic equity or debt investments held by the business segment when their fair value falls below the recorded book value. It indicates a loss in the perceived value of external partnerships or minority stakes, often signaling challenges in the underlying venture or market conditions. High or frequent impairment charges suggest potential risks in the segment's long-term investment strategy.
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — impairment of strategic investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude